ARCHIVES

Report Urges Changes To Cut Activation Times For NCI Phase III Trials.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

Bevacizumab Prolongs Survival In Patients With Advanced Colorectal Cancer

November 26, 2004

Cancer Letter Editor Wine Reporting Awards

June 11, 1999

Ohio Legislature Gives $1 Million To Cancer Control

August 19, 1983

NTP Board Okays Modification Of Bioassay Protocols

April 9, 1982

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

September 26, 2014

NCI prepares for third hearing on conflicts of interest.

June 18, 2004